Eltrombopag in severe immune thrombocytopenia secondary to connective tissue disease: a report of 17 patients and literature review

Li, Wenjing; Wang, Dandan; Li, Ma; Zhu, Yimei; Wang, Fan; Hua, Bingzhu; Wang, Hong; Feng, Xuebing

doi:10.1007/s10067-022-06464-w

Cited by 3 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eltrombopag is an orally administered, US Food and Drug Administration‐approved TPO‐RA that treats both primary ITP and CTD‐ITP. A favorable response to the drug was achieved in 70%–80% of all patients within 3–4 weeks 18,19 . However, the response was attenuated over time, and eltrombopag induced thrombosis in certain patients with aPL.…”

Section: Figurementioning

confidence: 99%

Intention to treat: The management of connective tissue disease‐related immune thrombocytopenia

Fu,

Zhao,

2023

Int J of Rheum Dis

View full text Add to dashboard Cite

Section: Figurementioning

confidence: 99%

Intention to treat: The management of connective tissue disease‐related immune thrombocytopenia

Fu,

Zhao,

2023

Int J of Rheum Dis

View full text Add to dashboard Cite

Effectiveness and safety of eltrombopag in connective tissue disease patients with refractory immune thrombocytopenia: a retrospective study

Jiang,

Shu,

2024

Rheumatology Advances in Practice

View full text Add to dashboard Cite

Objectives We aimed to investigate the safety and effectiveness of eltrombopag for adult patients with refractory immune thrombocytopenia (ITP) secondary to connective tissue disease (CTD). Methods This is a single center, retrospective cohort and propensity score-matched study. Data from CTD-ITP patients treated with eltrombopag between January 2019 and January 2023 were retrospectively analyzed. Baseline characteristics and follow-up information were recorded. CTD patients without ITP were matched to identify the risk factors associated with CTD-ITP performed by Logistic regression analysis. Results Twenty patients were enrolled, including 5 systemic lupus erythematosus (SLE), 9 Sjögren's syndrome (SS) and 6 undifferentiated connective tissue disease (UCTD). Nineteen (95%) patients were female and the median age was 59 years. Logistic regression analysis showed that anaemia (OR = 8.832, p = 0.007) was associated with increased risk of ITP, while non-erosive arthritis (OR = 0.045, p = 0.001) and interstitial lung disease (OR = 0.075, p = 0.031) were associated with reduced risk. Fourteen patients (70%) achieved a complete response (CR) and one (5%) achieved a partial response (PR). The median response time was 14 days. The median platelet count was 8.5 × 109/l at baseline of eltrombopag, and increased to 122 × 109/l after 4 weeks. No adverse events were observed. Conclusions Eltrombopag appears to be effective, safe, and well-tolerated in refractory ITP patients with CTD; larger studies are needed to confirm the generalizability of these findings.

show abstract

Correlation between PLT and SII, PLR and PDW in Patients with Connective Tissue Disease Complicated with Thrombocytopenia

宋¹

2023

ACM

View full text Add to dashboard Cite

Eltrombopag in severe immune thrombocytopenia secondary to connective tissue disease: a report of 17 patients and literature review

Cited by 3 publications

References 22 publications

Intention to treat: The management of connective tissue disease‐related immune thrombocytopenia

Intention to treat: The management of connective tissue disease‐related immune thrombocytopenia

Effectiveness and safety of eltrombopag in connective tissue disease patients with refractory immune thrombocytopenia: a retrospective study

Correlation between PLT and SII, PLR and PDW in Patients with Connective Tissue Disease Complicated with Thrombocytopenia

Contact Info

Product

Resources

About